A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual antiplatelet therapy (DAPT) is safe and effective in patients undergoing percutaneous coronary intervention (PCI) for unprotected left main coronary artery (uLMCA) disease. These findings are courtesy of the IDEAL-LM trial, which compared BP-EES plus four months of DAPT to a conventional durable polymer everolimus-eluting stent (DP-EES) followed by 12 months of DAPT.

Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not increase myocardial infarction (MI) or stent thrombosis (ST) in high bleeding risk (HBR) patients treated with a contemporary drug-eluting stent.

Ancora Heart Inc. announced results from an interim analysis of heart failure patients treated in the CorCinch FMR study, a U.S. early feasibility study. CorCinch FMR evaluated the safety of the investigational AccuCinch Ventricular Repair System designed for the treatment of systolic heart failure. The data was presented at the 31st Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, Sept. 24-29 in San Francisco.

EchoPixel introduced what it calls the first-ever intraoperative software to provide naked-eye, touchless interactive 3-D anatomical imaging to support structural heart procedures in the cath lab, operating room (OR) and hybrid OR. The introduction was made at the Transcatheter Cardiovascular Therapeutics (TCT) 2019 meeting, September 25-29, in San Francisco. The company will showcase the turnkey intraoperative solution, which is pending U.S. Food and Drug Administration (FDA) 510(k) clearance, as part of its existing integrated suite of mixed reality software solutions that assist cardiologists and surgeons with visualization of live 3-D medical images during a procedure for more precise catheter and device placement and personalized planning.